about
Analysis of eight cases of neonatal meningitis and sepsis due to Enterobacter sakazakiiSusceptibilities of 45 clinical isolates of Proteus penneriAlternative strategies for proof-of-principle studies of antibacterial agentsComparison of ceftazidime with cefamandole for therapy of community-acquired pneumoniaTherapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodologyFailure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infectionIn vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibioticsA randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilliComparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acidAnnual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites.Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins.Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalisCharacterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibilityIn vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditisIn vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life.Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.In vitro activity of imipenem--a review.Efficacy and safety of ceftriaxone in serious pediatric infections.Pharmacokinetics of cefoperazone in full-term and premature neonates.Mechanism of resistance to some cephalosporins in Staphylococcus aureus.Comparison of susceptibilities of anaerobic bacteria to cefmenoxime, ceftriaxone, and other antimicrobial compounds.Synthesis and in vitro antibacterial activity of cephalosporins with a pyridinium substituent carrying an isoxazole moiety at the C-3 position.Ceftizoxime (FK 749) in vitro antibacterial activity.Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome.Intraoperative positive fluid balance improves tissue diffusion of ceftizoxime.Antibiotic use in cystic fibrosis. 1984.In-vitro activity of ciprofloxacin and sixteen other antimicrobial agents against blood culture isolates.Imipenem/cilastatin.Evaluation of cefotaxime in bacterial infections.Sensitivity of 523 blood culture isolates to 33 antibiotics.Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.
P2860
Q24651206-6ACFF5C4-1248-4570-B6C5-BA672131308DQ24669683-2B6430EC-2B7A-45DA-BE15-4BB1185CFE08Q26850895-61D268E8-1C2A-4848-8EEF-21BD639EE6AAQ30451309-BCDF2845-A1F0-41B8-9F2B-600C509E1CC1Q34031360-DA6D890F-A1CE-42A1-9057-B1A8EF806050Q35247398-53930995-83DE-4234-8C9C-83F9A4F54E92Q35538487-10D4EBA1-334E-4CEE-99DA-B31089B1CDA5Q35644605-CFEC75E1-F21C-4C5A-90F6-BCD42803369CQ35648068-8F9823D9-6AB8-4654-BD19-D6281BCEDFDDQ35749458-1C04AA10-3DF8-4E6F-A4FB-069B06C21E72Q35749565-C30138ED-70F2-4D79-9693-F2D7BF310C64Q37158142-710F2300-8E87-4F27-A1B1-392C87612FCBQ37189232-76596125-1642-4198-B416-66F3EBFBD81AQ37258086-8C567F75-F3AE-4590-B396-58D321A79FFAQ37269692-EB4AC5E3-857E-45AD-AC05-3DA9B690A107Q38272526-6641C794-D219-40EC-8ABF-C9F0AC297E4DQ39833604-F7450412-9568-456B-88C1-A66D4AEE8BEAQ39834084-54010CB0-50BE-4A16-A93A-3D5F25BEFB62Q39834956-168FAB04-A8ED-4F28-BC06-BEE25BE9289CQ39835731-F6960BBD-9197-4243-BA6C-F4FE696F52C7Q39851746-8E16AFDF-75AE-4AB4-8395-5248B80175BDQ40192467-82A3103F-2F50-427E-B713-34904AD18BCAQ41833169-A7F53A2A-BA01-4520-ADF7-D9E3CF9D861EQ41892422-4531815D-2FC9-403A-8FCB-16041693C0C8Q42115560-CEEADE01-B258-4CB0-9716-ECB6EE269FA8Q42253836-50C1A70B-A216-4A84-A5E4-9BA952616C36Q43599116-B995ECFC-72EB-45CF-A1A5-C2602AA4E062Q44241791-9A8FD231-8332-4C39-BFF3-E7DAB55ECB9CQ44666933-FF2EE64F-85A8-413B-BCB5-44D7A32BD6E9Q46471545-6BBD26FE-688C-4725-AA1F-3E0A8778B573Q48590601-447069F8-C1D6-4525-8083-EC7C9B26D9CFQ50164239-B3227F36-39AE-4A0B-AA9B-DD334CE29215Q54467055-F448AAF9-50AB-4B1E-97F4-220B620F1F72Q54477213-A7013212-DA61-432B-A6B8-07FEA2170B71Q54482265-8CC93906-2652-4A02-9D97-6A56E57293E5Q54493215-95EAC5C5-BD4D-4DC8-8B15-075235579D75
P2860
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Comparative activities of 13 beta-lactam antibiotics
@ast
Comparative activities of 13 beta-lactam antibiotics
@en
type
label
Comparative activities of 13 beta-lactam antibiotics
@ast
Comparative activities of 13 beta-lactam antibiotics
@en
prefLabel
Comparative activities of 13 beta-lactam antibiotics
@ast
Comparative activities of 13 beta-lactam antibiotics
@en
P2860
P356
P1476
Comparative activities of 13 beta-lactam antibiotics
@en
P2093
Muytjens HL
van der Ros-van de Repe J
P2860
P304
P356
10.1128/AAC.21.6.925
P407
P577
1982-06-01T00:00:00Z